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Introduction {#sec005}
============

Colorectal cancer (CRC) is one of the most common malignancies, which ranks the third in the cancer morbidity and the second in the cancer mortality worldwide, with an annual 1.3 million new CRC cancer cases and 694,000 deaths according to the GLOBOCAN estimations\[[@pone.0179670.ref001], [@pone.0179670.ref002]\]. Although advancements have been made regarding the available treatment strategies, the overall survival rate of CRC patients has not improved dramatically\[[@pone.0179670.ref003], [@pone.0179670.ref004]\]. Relapse and metastasis are major factors for the poor outcome of CRC patients\[[@pone.0179670.ref005]\]. The occurrence of CRC involves multi-factorial and complex steps in which the abnormal gene expression plays a vital role\[[@pone.0179670.ref006]\]. Therefore, it is emergently necessary to identify novel molecular markers for the early detection, prognosis prediction and therapy evaluation for CRC.

Long non-coding RNAs (lncRNAs), which are defined as RNA molecules of larger than 200 nucleotides in length without protein-coding capacity, regulate gene expression at the epigenetic, transcriptional or posttranscriptional level and once were considered to be transcriptional noise\[[@pone.0179670.ref007]--[@pone.0179670.ref009]\]. Recently, accumulating evidences showed that lncRNAs played pivotal roles in various cancers and were associated with tumor cell proliferation, apoptosis, invasion and metastasis\[[@pone.0179670.ref010], [@pone.0179670.ref011]\]. For example, plasmacytoma variant translocation 1 gene (PVT1) could inhibit the apoptosis of breast cancer cells \[[@pone.0179670.ref012]\]. LncRNA H19 was significantly up-regulated in the plasma of Gastric Cancer (GC) patients, and could be a potential non-invasive diagnostic biomarker in GC\[[@pone.0179670.ref013]\]. In 2016 Huang *et al*. \[[@pone.0179670.ref014]\] reported that lncRNA DGCR5 was down-regulated in hepatocellular carcinoma and correlated with poor prognosis. In non-small cell lung cancer, upregulation of long non-coding RNA ATB, a TGF-β-activated lncRNA, indicated a poor prognosis by regulating cell proliferation and metastasis\[[@pone.0179670.ref015]\]. Recent mounting studies have shown that lncRNAs are potential diagnostic and prognostic biomarkers of CRC.

Up to now, some lncRNAs have been shown to be expressed aberrantly in CRC, such as SNHG20\[[@pone.0179670.ref016]\], TUG1\[[@pone.0179670.ref017]\], and 91H\[[@pone.0179670.ref018]\]. In 2015, Chen *et al*. \[[@pone.0179670.ref019]\] found that FEZF1 antisense RNA1 (FEZF1-AS1) was upregulated in CRC tissues and could serve as a potential therapeutic target in CRC. Colon cancer-associated transcript 1 (CCAT1) activated by c-Myc, plays an oncogenic role in CRC development and metastasis\[[@pone.0179670.ref020]\]. Promoter of CDKN 1A antisense DNA damage activated RNA (PANDAR) could affect epithelial--mesenchymal transition through inhibiting N-cadherin, vimentin, β-catenin, Snail and Twist expression and increasing the expression levels of E-cadherin. The results indicted that PANDAR could be a biomarker for poor prognosis of CRC\[[@pone.0179670.ref021]\]. Many studies were performed to investigate the prognostic value of lncRNAs in CRC. However, single study may be inaccurate and insufficient, Thus, studies should be analyzed systematically to gain a better insight into the potential clinical values of lncRNAs in CRC. Although some reviews have reported evaluation of the clinical values of multiple lncRNAs in CRC, meta-analysis of lncRNAs in CRC has not yet to be performed. Therefore, relevant articles were collected to evaluate the relationship between lncRNAs expression and clinical outcomes in CRC.

Materials and methods {#sec006}
=====================

Publication search {#sec007}
------------------

We retrieved Pubmed, Web of Science, Embase and Cochrane Library to obtain all relevant articles. The literature search was limited to the English language and ended in January 22, 2017. The search strategy used both MeSH terms and free-text words to increase the sensitivity of the search. The search terms included: ("Long non-coding RNA", "lncRNA", "LincRNA", "Long ncRNA", "Long intergenic non-coding RNA") AND ("CRC", "colorectal cancer", "colorectal neoplasm", "colorectal tumor", "rectal neoplasm", "rectal cancer", "rectal tumor", "colon neoplasm", "colon cancer", "colon tumor"). Relevant articles were also reviewed manually in case of the omission of any potentially relevant literature.

Inclusion and exclusion criteria {#sec008}
--------------------------------

The eligible studies met the following criteria: patients were diagnosed with colorectal cancer; relationship between lncRNAs and colorectal cancer was investigated; the prognostic value of lncRNAs was evaluated; the association between lncRNA expression and survival (OS, disease-free survival \[DFS\], and disease-specific survival \[DSS\]) was performed; and the survival curve or sufficient relevant data was provided to obtain hazard ratios (HR) for survival rates and their 95% confidence intervals (95% CI). Exclusion criteria were as follows: duplicate studies; sample population consisted of less than 40 cases; non-English papers; letters; review articles; case reports; lack of original data; non-human studies.

Data quality assessment and extraction {#sec009}
--------------------------------------

Two investigators (JEW and SLD) extracted and reviewed the essential information of each eligible study independently according to pre-specified inclusion and exclusion criteria. The following data were extracted: the first author's name, year of publication, country, sample size, tumor type, cutoff value, detection method, outcome, analysis type and quality score. The quality of the included studies was assessed with the Newcastle-Ottawa Scale (NOS) criteria for cohort studies \[[@pone.0179670.ref022]\]. HRs and their 95% CIs were extracted directly from the original articles or calculated from Kaplan-Meier survival curve by HR digitizer software Engauge 4.1 as described by Thierny et al\[[@pone.0179670.ref023]\]. Any discrepancies on data extraction and quality assessment were resolved through discussion with a third reviewer (MXY). The quality of all the included studies was assessed by The Newcastle-Ottawa Scale (NOS) method. The NOS scores ranged from 0 to 9, and a study with the NOS score more than 6 was regarded as high quality.

Statistical analysis {#sec010}
--------------------

Statistical analysis was conducted with Review Manager5.2 (The Cochrane Collaboration, Software Update, Oxford, UK) and stata12.0 (STATA Corporation, College Station, TX, USA). HRs and its 95% CI were used to evaluate the association between lncRNAs and survival in CRC. HR \> 1 indicated that the patients with high lncRNAs expression had a poor prognosis. Conversely, HR\<1 implied the patients with low lncRNAs expression had a good prognosis. ORs and 95% CIs were used to assess the association between lncRNAs and clinical features in patients of CRC. The features included gender, tumor size, tumor differentiation, distant metastasis, lymph node status, TNM stage and tumor invasion depth. Heterogeneity among the eligible studies was assessed with the Q test and *I*^2^ statistic, and the *I*^2^ value indicated the degree of heterogeneity. A *p*-value\<0.05 or *I*^2^\>50% indicated significant heterogeneity, in which case a random-effects model was used, if not, a fixed-effects model was used. Publication bias was evaluated by Begg's test and *P*\>0.05 indicated no significant bias among studies. Sensitivity analyses were performed to access the stability of the meta-analysis results. All the *P* values were determined by two-sided tests.

Results {#sec011}
=======

Study characteristics {#sec012}
---------------------

As shown in the flow diagram ([Fig 1](#pone.0179670.g001){ref-type="fig"}), a total of 986 records were retrieved from Pubmed, Web of Science, Embase and Cochrane Library. 524 duplicate reports were excluded. After the titles and abstracts were reviewed, 308 irrelevant articles were excluded. Subsequently, the 154 remaining full-text articles were assessed, 120 were found to be ineligible due to lack of sufficient data for further analysis, 34 studies were eligible for the current meta-analysis, including 30 on OS\[[@pone.0179670.ref016]--[@pone.0179670.ref020], [@pone.0179670.ref024]--[@pone.0179670.ref048]\], 7 on DFS\[[@pone.0179670.ref019], [@pone.0179670.ref025], [@pone.0179670.ref034], [@pone.0179670.ref036], [@pone.0179670.ref037], [@pone.0179670.ref042], [@pone.0179670.ref049]\], 1 on RFS\[[@pone.0179670.ref024]\], 2 on DSS\[[@pone.0179670.ref050], [@pone.0179670.ref051]\], and 29 on clinicopathological features\[[@pone.0179670.ref016]--[@pone.0179670.ref020], [@pone.0179670.ref024]--[@pone.0179670.ref029], [@pone.0179670.ref031], [@pone.0179670.ref032], [@pone.0179670.ref034]--[@pone.0179670.ref037], [@pone.0179670.ref039]--[@pone.0179670.ref046], [@pone.0179670.ref048]--[@pone.0179670.ref051]\].

![The flow diagram of this meta-analysis in CRC.](pone.0179670.g001){#pone.0179670.g001}

Among these 34 studies, a total of 3653 patients were represented. The mean size of patient sample was 111 (range from 48 to 239). The most recent publication date was January 22, 2017. Among the eligible articles, 31 were from China, 3 from Japan and 1 from Czech Republic. In the including 34 studies, 29 articles analyzed the relationship between the expression of lncRNAs and gender\[[@pone.0179670.ref016]--[@pone.0179670.ref020], [@pone.0179670.ref024]--[@pone.0179670.ref029], [@pone.0179670.ref031], [@pone.0179670.ref032], [@pone.0179670.ref034]--[@pone.0179670.ref037], [@pone.0179670.ref039]--[@pone.0179670.ref046], [@pone.0179670.ref048]--[@pone.0179670.ref051]\], 7 studies estimated the association between lncRNAs and tumor size\[[@pone.0179670.ref019], [@pone.0179670.ref024], [@pone.0179670.ref025], [@pone.0179670.ref027], [@pone.0179670.ref041], [@pone.0179670.ref042], [@pone.0179670.ref048]\], 16 studies estimated the association between lncRNAs and tumor differentiation\[[@pone.0179670.ref016], [@pone.0179670.ref017], [@pone.0179670.ref019], [@pone.0179670.ref024], [@pone.0179670.ref025], [@pone.0179670.ref028], [@pone.0179670.ref029], [@pone.0179670.ref034], [@pone.0179670.ref036], [@pone.0179670.ref037], [@pone.0179670.ref039], [@pone.0179670.ref040], [@pone.0179670.ref043], [@pone.0179670.ref045], [@pone.0179670.ref046], [@pone.0179670.ref048]\], 24 studies were about lymph node metastasis(LNM)\[[@pone.0179670.ref016]--[@pone.0179670.ref020], [@pone.0179670.ref026], [@pone.0179670.ref027], [@pone.0179670.ref029]--[@pone.0179670.ref032], [@pone.0179670.ref034]--[@pone.0179670.ref037], [@pone.0179670.ref039], [@pone.0179670.ref040], [@pone.0179670.ref042]--[@pone.0179670.ref046], [@pone.0179670.ref048], [@pone.0179670.ref050]\], and 20 were about distant metastasis\[[@pone.0179670.ref016], [@pone.0179670.ref018]--[@pone.0179670.ref020], [@pone.0179670.ref025], [@pone.0179670.ref027]--[@pone.0179670.ref029], [@pone.0179670.ref035]--[@pone.0179670.ref037], [@pone.0179670.ref039], [@pone.0179670.ref040], [@pone.0179670.ref042]--[@pone.0179670.ref046], [@pone.0179670.ref048], [@pone.0179670.ref050]\], 18 studies demonstrated that lncRNAs were correlated with TNM stage\[[@pone.0179670.ref018], [@pone.0179670.ref020], [@pone.0179670.ref025], [@pone.0179670.ref027], [@pone.0179670.ref029], [@pone.0179670.ref035]--[@pone.0179670.ref039], [@pone.0179670.ref041], [@pone.0179670.ref042], [@pone.0179670.ref044], [@pone.0179670.ref046], [@pone.0179670.ref048], [@pone.0179670.ref050]--[@pone.0179670.ref052]\], 17 studies reported the association between lncRNAs and tumor invasion depth\[[@pone.0179670.ref016], [@pone.0179670.ref018], [@pone.0179670.ref019], [@pone.0179670.ref026]--[@pone.0179670.ref028], [@pone.0179670.ref031], [@pone.0179670.ref036], [@pone.0179670.ref039], [@pone.0179670.ref041], [@pone.0179670.ref042], [@pone.0179670.ref044]--[@pone.0179670.ref046], [@pone.0179670.ref048], [@pone.0179670.ref050], [@pone.0179670.ref051]\]. The main information and data were summarized in [Table 1](#pone.0179670.t001){ref-type="table"}.

10.1371/journal.pone.0179670.t001

###### Characteristics of studies included in this meta-analysis.

![](pone.0179670.t001){#pone.0179670.t001g}

  Author Year of publication   Country          LncRNAs         Sample size (high/low)   Tumor type   Cutoff           Detection method   Outcome   Analysis type        Quality score
  ---------------------------- ---------------- --------------- ------------------------ ------------ ---------------- ------------------ --------- -------------------- ---------------
  Qi2013                       China            LOC285194       33/48                    CRC          mean             qRT-PCR            DSS       Multivariate         8
  Shi2014                      China            RP11-462C24.1   32/54                    CRC          mean             qRT-PCR            DSS       Multivariate         8
  Li2016                       China            SNHG20          54/53                    CRC          2.86-fold        qRT-PCR            OS        Multivariate         7
  SunJ2016                     China            TUG1            38/23                    CRC          fivefold         qRT-PCR            OS        Kaplan-Meiercurves   7
  SunY2016                     China            ANRIL           53/44                    CRC          RE1.5            RT-qPCR            OS        Kaplan-Meiercurves   7
  Lu2016                       China            PANDAR          62/62                    CRC          median           qRT-PCR            OS        Multivariate         8
  Ge2013                       China            PCAT-1          50/58                    CRC          ROC              qRT-PCR            OS        Multivariate         7
  Yin2014                      China            GAS5            33/33                    CRC          mean             qRT-PCR            OS        Multivariate         6
  Yin2015                      China            MEG3            31/31                    CRC          mean             qRT-PCR            OS        Multivariate         8
  Ye2015                       China            CLMAT3          45/45                    CRC          RE               qRT-PCR            OS        Multivariate         8
  Takahashi2013                Japan            PVT-1           131/33                   CRC          MYC expression   qRT--PCR           OS        Multivariate         7
  Svoboda2014                  Czech Republic   HOTAIR          36/37                    CRC          ROC              RT-qPCR            OS        Multivariate         8
  WangW2016                    China            ZFAS1           79/80                    CRC          median           qRT-PCR            RFS/OS    Multivariate         7
  WangF2016                    China            AFAP1-AS1       26/26                    CRC          median           qRT-PCR            DFS/OS    Multivariate         8
  Zheng2014                    China            MALAT1          73/73                    CRC          RE 6.15          qRT--PCR           DFS/OS    Multivariate         7
  Iguchi2015                   Japan            lncRNA-ATB      62/62                    CRC          median           RT-PCR             DFS       Kaplan-Meiercurves   8
  Ni2015                       China            UCA1            27/27                    CRC          median           RT-qPCR            OS        Kaplan-Meiercurves   8
  LiY2015                      China            NEAT1           110/129                  CRC          2-fold           RT-PCR             DFS/OS    Multivariate         8
  Han2016                      China            H19             48/35                    CRC          3-fold           qRT-PCR            DFS/OS    Multivariate         7
  Liu2016                      China            CRNDE-h         71/71                    CRC          median           qRT-PCR            OS        Multivariate         7
  Deng2014                     China            91H             30/42                    CRC          RE2.86           qRT-PCR            OS        Multivariate         6
  Wu2014                       China            HOTAIR          40/80                    CC           5-fold           qRT-PCR            OS        Multivariate         8
  Kogo2011                     Japan            HOTAIR          20/80                    CRC          RE 0.273         qRT-PCR            OS        Kaplan-Meiercurves   7
  Han2014                      China            UCA1            37/43                    CRC          mean             RT-qPCR            OS        Kaplan-Meiercurves   7
  He2014                       China            CCAT1           24/24                    CC           median           qPCR               OS        Kaplan-Meiercurves   8
  Liu2015                      China            DANCR           52/52                    CRC          median           qRT-PCR            DFS/OS    Multivariate         8
  Guo2015                      China            FTX             75/112                   CRC          median           qRT-PCR            OS        Multivariate         7
  Ren2015                      China            HOTTIP          77/79                    CRC          median           qRT-PCR            OS        Multivariate         6
  Chen2016                     China            FEZF1-AS1       89/64                    CRC          \-               RT-PCR             OS        Multivariate         7
  Chen2016                     China            FEZF1-AS1       89/64                    CRC          \-               RT-PCR             DFS       Kaplan-Meiercurves   8
  Cao2016                      China            SPRY4-IT1       36/48                    CRC          2.87-fold        qRT-PCR            OS        Multivariate         8
  Jiang2016                    China            UCA1            61/60                    CRC          median           qRT-PCR            OS        Multivariate         7
  Bian2015                     China            UCA1            45/45                    CRC          2-fold           qRT-PCR            OS        Multivariate         7
  Qiu2015                      China            LINC01296       80/80                    CRC          GAPDH            GEO                OS        Multivariate         6

Abbreviations: LncRNA: Long-coding RNA; CRC: Colorectal Cancer; CC: Colon Cancer; RE: Relative expression; RT-PCR: reverse transcription -polymerase chain reaction; qPCR: Real-time-PCR; qRT-PCR: Quantities reverse transcription-PCR; OS: Overall survival; DFS: Disease-free survival; DSS: Disease-specific survival; NA:Not available.

Global analysis between lncRNA transcription level and CRC survival {#sec013}
-------------------------------------------------------------------

A total of 30 studies of 3361 patients reported OS of CRC. HRs and corresponding 95% CIs of OS were extracted from the included studies. The estimated pooled HR showed a significant association between lncRNAs and OS in CRC patients (HR = 2.08, 95% CI = 1.68--2.57, *P*\<0.001, *I*^2^ = 70%) ([Fig 2](#pone.0179670.g002){ref-type="fig"}). There are two articles \[[@pone.0179670.ref020], [@pone.0179670.ref039]\] that reported the relationship between the expression level of lncRNAs and OS of colon cancer (HR = 4.11, 95% CI = 1.65--10.28, *P* = 0.002, *I*^2^ = 0%). The increased expressions of SPRY4-IT1, FEZF1-AS1, 91H, PCAT-1, H19, CCAT1, UCA1, HOTAIR, SNHG20, NEAT1, DANCR, CRNDE-h, PANDAR, HOTTIP, TUG1, ANRIL, PVT-1, AFAP1-AS1, ZFAS1 and CLMAT3 were associated with poor prognosis by promoting the proliferation and metastasis of CRC. Meanwhile, the decreased expressions of GAS5, LINC01296, LOC285194, RP11-462C24.1 and MEG3 were related to poor prognosis.

![Forest plot for the association between lncRNAs expression levels with overall survival in CRC.](pone.0179670.g002){#pone.0179670.g002}

For OS, a significant degree of heterogeneity (*I*^2^ = 70%, *p*\<0.001) was determined. Meta-regression analysis and subgroup analysis by sample size, analysis type, cut off values, and NOS score were also performed ([Table 2](#pone.0179670.t002){ref-type="table"}). The cutoff value of mean indicated no statistical significance (HR = 0.296, 95% CI = 0.02--4.05). However, other factors including sample size, analysis type, NOS scores, and weight did not change the significant prognostic impact of high lncRNAs expression level on OS. Subgroup analysis and meta-regression analysis failed to reveal the source of heterogeneity ([S1 Fig](#pone.0179670.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0179670.t002

###### Subgroup meta-analysis of pooled HRs for OS.
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  Categories                                 No. of studies   No. of patients   HR (95% CI) for OS   Meta-regression P-value   Heterogeneity   
  ------------------------------------------ ---------------- ----------------- -------------------- ------------------------- --------------- ---------
  \[[@pone.0179670.ref001]\] OS              30               3361              2.08 (1.68--2.57)                              70              \<0.001
  \[[@pone.0179670.ref002]\]No.of patients                                                           0.715                                     
   ≥100                                      17               2500              2.16(1.62--2.88)                               74              \<0.001
   \<100                                     13               851               1.96 (1.46--2.63)    53                        0.01            
  \[[@pone.0179670.ref003]\] Analysis type                                                           0.863                                     
  Multivariate                               24               2862              2.09(1.64--2.68)                               75              \<0.001
  Survival curves                            6                951               1.76(1.37--2.26)                               0               0.81
  \[[@pone.0179670.ref004]\]Cut-off values                                                           0.243                                     
   Mean                                      3                298               0.29(0.02--4.05)                               70              0.03
   Median                                    10               1237              2.22(1.70--2.90)                               54              0.02
   Others                                    16               1943              2.17(1.60--2.95)                               71              \<0.001
  \[[@pone.0179670.ref005]\] NOS score                                                               0.853                                     
   \>7                                       11               1243              2.35(2.03--2.73)                               68              0.0005
   ≤7                                        19               2298              2.06 (1.57--2.70)                              69              \<0.001
  \[[@pone.0179670.ref006]\] Weight                                                                  0.726                                     
   ≥5%                                       5                615               1.95(1.33--2.86)                               89              \<0.001
   \<5%                                      24               2746              2.13(1.63--2.80)                               61              \<0.001

CRC: Colorectal Cancer; TNM: Tumor node metastasis; I^2^\>50% with the random-effects model; I^2^\<50% with the fixed-effects model.

In the including studies, HOTAIR and UCA1 were investigated in three and four studies respectively. The other lncRNAs were performed in single study. We then conducted a meta-analysis on the relationship between HOTAIR/ UCA1 expression and OS of CRC patients. We found that high HOTAIR expression could predict short OS (HR = 3.43, 95% CI = 1.74--6.74, *P* = 0.0004, *I*^2^ = 0%) ([Fig 3A](#pone.0179670.g003){ref-type="fig"}). Besides, a poor prognosis in CRC was found in the upregulated levels of UCA1(HR = 2.12, 95% CI = 1.51--3.00, *P*\<0.001, *I*^2^ = 0%) ([Fig 3B](#pone.0179670.g003){ref-type="fig"}).

![Forest plots of studies evaluating hazard ratios of up-regulated lncRNAs and the overall survival of CRC patients.\
A. HOTAIR; B. UCA1.](pone.0179670.g003){#pone.0179670.g003}

The prognostic significance of lncRNAs in DFS was evaluated in seven studies\[[@pone.0179670.ref019], [@pone.0179670.ref025], [@pone.0179670.ref034], [@pone.0179670.ref036], [@pone.0179670.ref037], [@pone.0179670.ref042], [@pone.0179670.ref049]\] with 901 patients and that in DSS was examined in two studies \[[@pone.0179670.ref050], [@pone.0179670.ref051]\] with 167 patients ([Table 1](#pone.0179670.t001){ref-type="table"}). There was only one study showed the association between lncRNAs expression level and RFS \[[@pone.0179670.ref024]\] and therefore was ruled out from the meta-analysis. The up-regulated expression of lncRNAs were significantly associated with DFS (HR = 1.79, 95% CI = 1.54--2.08, *P*\<0.001, *I*^*2*^ = 6%) ([Fig 4A](#pone.0179670.g004){ref-type="fig"}), meanwhile, the down-regulated expression of lncRNAs was significantly correlated with DSS in CRC (HR = 0.01, 95% CI = 0.02--0.54, *P* = 0.007, *I*^*2*^ = 14%) ([Fig 4B](#pone.0179670.g004){ref-type="fig"}).

![Meta-analysis of the pooled HRs of DFS and DSS for CRC patients.\
A.DFS; B. DSS.](pone.0179670.g004){#pone.0179670.g004}

Correlation of lncRNAs with clinicopathological characteristics {#sec014}
---------------------------------------------------------------

In order to determine whether the expression of lncRNA was related to the clinical pathological characteristics, the clinicopathological data was collected for the meta-analysis. As shown in [Table 3](#pone.0179670.t003){ref-type="table"}, OR\>1 implied that high levels of lncRNAs might be a risk factor in the features. In CRC, lncRNA transcription level was significantly associated with tumor differentiation (OR = 0.51, 95% CI = 0.34--0.77, P = 0.001, random-effect model), lymph node metastasis (OR = 1.63, 95% CI = 1.23--2.17, P = 0.0007, random-effect model), distant metastasis (OR = 2.06, 95% CI = 1.29--3.30, P = 0.002, random-effect model), TNM stage (OR = 0.44, 95% CI = 0.32--0.62, *P*\<0.001, random-effect model), tumor invasion depth (OR = 0.48, 95% CI = 0.39--0.60, *P*\<0.001, fixed-effect model), and tumor size (OR = 0.52, 95% CI = 0.31--0.88, *P* = 0.02, random-effect model). However, no significant correlation was found with gender (OR = 0.88, 95% CI = 0.76--1.02, *P* = 0.08, fixed-effect model) ([S2 Fig](#pone.0179670.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0179670.t003

###### Association between high levels of lncRNAs and characteristics of patients with CRC.
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  Clinicopathological Parameters                   Studies   Number of patients   Relative risk of higher lncRNAs OR (95% CI)   Significant Z   Test p-value   Heterogeneity I^2^ (%)   Test p-value   Model
  ------------------------------------------------ --------- -------------------- --------------------------------------------- --------------- -------------- ------------------------ -------------- ----------------
  Gender (Female vs. male)                         29        3125                 0.88(0.76--1.02)                              1.74            0.08           0                        0.66           Fixed effects
  Tumor size (\<5 vs ≥5)                           7         672                  0.52(0.31--0.88)                              2.43            0.02           65                       0.009          Random effects
  Tumor differentiation (Moderate/well vs. poor)   16        1845                 0.51(0.34--0.77)                              3.24            0.001          70                       \<0.001        Random effects
  Lymph node metastasis (Positive vs. negative)    24        2748                 1.63(1.23--2.17)                              3.38            0.0007         66                       \<0.001        Random effects
  Distant metastasis (Positive vs. negative)       20        1998                 2.06(1.29--3.30)                              3.03            0.002          68                       \<0.001        Random effects
  TNM stage (I--II vs. III--IV)                    18        1770                 0.44(0.32--0.62)                              4.84            \<0.001        62                       0.0002         Random effects
  Tumor invasion depth (T1-T2 vs. T3-T4)           17        1822                 0.48(0.39--0.60)                              6.66            \<0.001        39                       0.05           Fixed effects

Abbreviations: CRC: Colorectal Cancer; TNM: Tumor node metastasis; I^2^\>50% with the random-effects model; I^2^\<50% with the fixed-effects model.

Sensitivity analyses {#sec015}
--------------------

To assess whether a single study might significantly affect the overall results, we performed a sensitivity analysis using Stata12.0 software. In the current study, removing any of the included studies had no significant influence on the estimated pooled results, which demonstrated that our analyses were relatively stable and credible ([Fig 5](#pone.0179670.g005){ref-type="fig"}). Because of the small number of studies, the sensitivity analysis was not analyzed for DSS.

![Sensitivity analyses of the studies.\
A. overall survival; B. disease-free survival; C. gender; D. tumor size (\<5 vs ≥5); E. tumor differentiation; F. lymph node metastasis; G. distant metastasis; H. TNM stage; I. Tumor invasion depth.](pone.0179670.g005){#pone.0179670.g005}

Publication bias {#sec016}
----------------

The publication bias of the present meta-analysis was evaluated by Bgger's test. All groups had no bias, due to all the values of *P*\>0.05([Fig 6](#pone.0179670.g006){ref-type="fig"}). For DSS group, the publication bias was not analyzed because of the small number of studies.

![Begg's test for publication bias.\
A. overall survival; B. disease- free survival C. gender; D. tumor size (\<5 vs ≥5); E. tumor differentiation; F. lymph node metastasis; G. distant metastasis; H. TNM stage; I. Tumor invasion depth.](pone.0179670.g006){#pone.0179670.g006}

Discussion {#sec017}
==========

Nowadays, CRC remains a major health problem and it is the third most common cause of cancer-related death wordwide\[[@pone.0179670.ref053]--[@pone.0179670.ref055]\]. Molecular Pathologic Epidemiology \[[@pone.0179670.ref056]\] is a relatively new, evolving field of epidemiology that is designed to clarify how various exposures affect initiation, transformation and progression of neoplasia\[[@pone.0179670.ref057]\]. It will continue to provide insights into carcinogenic process and help us to optimize prevention and treatment strategies\[[@pone.0179670.ref058]\]. Recently, a large number of studies demonstrated that the occurrence and progression of CRC was a multi-step process involving in lncRNAs dysregulation of multiple oncogenes and tumor suppressors. It is urgent to identify sensitive and specific biomarkers for early diagnosis and prognosis evaluation\[[@pone.0179670.ref035]\]. The up-regulation of FTX could serve as an important prognostic factor in CRC patients by promoting growth, migration, invasion and increasing colony formation in colorectal cancer cells\[[@pone.0179670.ref043]\]. Study from Cao *et al*. showed that up-regulated expression of SPRY4-IT1 dramatically shortened patients' survival time by EMT pathway\[[@pone.0179670.ref045]\]. In the CRC, MEG3 might act as a tumor suppressor gene and contribute to tumorigenesis through inhibiting cancer cell proliferation\[[@pone.0179670.ref030]\]. In addition, some researchers pointed out that H19 was associated with a poor prognosis in colorectal cancer, which promoted tumor growth by recruiting and binding to eIF4A3\[[@pone.0179670.ref037]\]. In order to search for a prognostic potential target for CRC, we performed a meta-analysis to examine the relationship between lncRNAs and prognosis of patients with CRC.

Emerging evidence have demonstrated that the association between lncRNAs and CRC. In 2014, Yin *et al*. suggested that the downregulated GAS5 was related with a poor prognosis and could serve as a candidate prognostic biomarker for OS\[[@pone.0179670.ref029]\]. Meanwhile, the elevated expression of 91H was regarded as a novel prognosis indicator that contributed to predict tumor metastasis and poor survival of patients with CRC\[[@pone.0179670.ref018]\]. In our meta-analysis, we explored the prognostic role of lncRNAs in CRC. The results implied that high lncRNA transcription level exhibited a significant risk factor for OS, DFS and DSS. For OS, the test for heterogeneity of included studies was significant (*I*^2^ = 70, *P*\<0.001). Although we employed subgroup analysis, meta-regression analysis and sensitivity analysis, all the methods failed to confirm the source of heterogeneity. For DSS, there were only two studies revealed its correlation with LncRNA expression, thus in the further, large-scale and more detailed studies may be needed to be recruited in the meta-analysis.

In our meta-analysis, HOTAIR was investigated in three studies and Urothelial carcinoma-associated 1 (UCA1) was detected in four studies. The increased expression of the two lncRNAs was associated with low survival rate of patients of CRC. UCA1 is an oncofoetal gene involved in embryonic development and carcinogenesis\[[@pone.0179670.ref035]\]. In 2015, Ni *et al*. illuminated that UCA1 could significantly enhance migration and invasion of CRC cells. Bian *et al*. found UCA1 promoted cell proliferation and chemoresistance in colorectal cancer by inhibiting miR-204-5p\[[@pone.0179670.ref048]\]. Furthermore, HOTAIR regulated expression of multiple genes in cooperation with PRC2 and was a novel molecule involved in the progression of CRC\[[@pone.0179670.ref040]\]. Therefore, it also was an independent prognostic factor for patients with CRC. Our results showed that the two lncRNAs had a significantly prognostic value in CRC.

In addition, we assessed the association of lncRNA transcription levels with the main clinicopathological features of CRC. Subgroup analysis indicated that lncRNA transcription was related to tumor size, tumor differentiation, lymph node metastasis, distant metastasis, TNM stage and tumor invasion depth. However, there was no correlation between lncRNAs expression and gender.

We have to admit that there are some limitations in our study. Firstly, most of the population in our studies were Chinese, so the conclusion of this study cannot be extended to all populations. Secondly, multiple lncRNAs were used to evaluate the prognosis of CRC, and there was a lack of specific CRC-related lncRNA for clinical evaluation. Thirdly, since there was only one study for each lncRNA in most cases, the prognostic value of each lncRNA may be overestimated. Furthermore, data of HR and 95% CIs were estimated from Kaplan--Meier survival curves in eight studies, which might be less accurate than that acquired directly from published statistics and might increase the potential bias.

Together, this meta-analysis for the first time evaluated the expressions of lncRNAs and clinical values of lncRNAs in CRC. The above analysis showed that lncRNAs were closely related with colorectal cancer, and it can be used as a promising indicator for prognostic of patients with CRC. However, larger-size and higher-quality studies are required to offer better insights into the prognostic value of lncRNAs patients with CRC.
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###### Forest plot of HRs for the association between lncRNAs expression levels and OS in cancer patients stratified by different subsets.

A. sample size; B. analysis type; C. cut-off valus; D. Nos score; E. weight.

(TIF)

###### 

Click here for additional data file.

###### Forest plot for the association between lncRNAs expression levels with characteristics of patients with CRC.

A. gender; B. tumor size (\<5 vs ≥5); C. tumor differentiation; D. lymph node metastasis; E. distant metastasis; F. TNM stage; G. Tumor invasion depth.

(TIF)

###### 

Click here for additional data file.
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